TY - JOUR
TI - Docetaxel and gemcitabine combination, as firs-tline treatment, in
patients with extensive disease small-cell lung cancer. A phase II study
of the Hellenic Cooperative Oncology Group
AU - Skarlos, DV
AU - Dimopoulos, AM
AU - Kosmidis, P
AU - Papakostas, P and
AU - Pavlidis, N
AU - Bacoyiannis, C
AU - Kiamouris, C
AU - Klouvas, G and
AU - Gogas, H
AU - Fountzilas, G
AU - Samantas, E
JO - Lung Cancer
PY - 2003
VL - 41
TODO - 1
SP - 107-111
PB - ELSEVIER SCI IRELAND LTD
SN - 0169-5002
TODO - 10.1016/S0169-5002(03)00154-5
TODO - extensive small cell lung cancer; docetaxel; gemcitabine
TODO - There is some evidence that taxanes and gemcitabine are effective
antitumor agents against small-cell lung cancer (SCLC). A total of 20
chemotherapy-naive patients with extensive disease (ED) SCLC, were
treated as a part of the first step of a phase II study, with docetaxel
50 mg/m(2) and gemcitabine 1000 mg/m(2), both administered on day 1 and
8 every 3 weeks up to a total of six cycles. For patients who progressed
after the first cycle or had stable disease after the second cycle of
chemotherapy, protocol treatment was stopped and further treatment with
the standard cisplatin or carboplatin-etoposide combination was
administered. Patients were in the vast majority mate smokers with a
good performance status. A total of 72 cycles was delivered while
patients managed to receive the 78 and 84% of the planned dose of
docetaxel and gemcitabine, respectively. Only six patients responded
partially and the trial ended prematurely since at least seven responses
were required among the first 19 patients. With a median follow-up of 13
months, median time to progression (TTP) was 8 months and median
survival 9.6 months. Hematological. and non-hematological toxicity was
generally acceptable while patients tolerated their treatment reasonably
well. In conclusion, docetaxel-gemcitabine showed a modest response rate
in chemotherapy-naive patients with ED SCLC. (C) 2003 Elsevier Science
Ireland Ltd. All rights reserved.
ER -